Discover a study that explored the effects of various metabolic abnormalities, such as central obesity and high blood ...

Dapagliflozin, a SGLT2 inhibitor used for type 2 diabetes, alleviates steatohepatitis and fibrosis in patients with ...

Diabetes drug dapagliflozin could also be beneficial for patients with progressive liver disease, a clinical trial has shown.

Follow-up reached a median 5.5 years overall. Adverse liver outcomes in question counted cirrhosis, decompensation, ...

While beer, soft drinks, milk tea, and ice cream are summertime staples for many, they may contribute to the progression of fatty liver disease if consumed excessively.

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...

The Global Liver Institute urges worldwide integration of liver health into diabetes and obesity care as steatotic liver ...